the DCA site - Updating you on DCA and Cancer

DCA Discussion Forum

Subject: "DCA enhances effectiveness of TPZ"     Previous Topic | Next Topic
Printer-friendly copy     Email this topic to a friend    
Conferences DCA Research Topic #61
Reading Topic #61
yuzai
Member since Apr-16-07
1 posts
Jul-06-07, 10:05 PM (PST)
Click to EMail yuzai Click to view user profileClick to add this user to your buddy list  
"DCA enhances effectiveness of TPZ"
 
   According to a latest research published on PNAS,104(22), 9445-9450(May 29, 2007), DCA can increase the effectiveness of hypoxia targeted therapies such as the hypoxic cytotoxin tirapazamine(TPZ) by inhibiting PDK1 activity.

what is TPZ? quote from wiki:

Tirapazamine (SR-4233) is an experimental anticancer drug that is activated to a toxic radical only at very low levels of oxygen (hypoxia). Such levels are common in human solid tumors, a phenomenon known as tumor hypoxia. Thus, tirapazamine is activated to its toxic form preferentially in the hypoxic areas of solid tumors. Cells in these regions are resistant to killing by radiotherapy and most anticancer drugs. Thus the combination of tirapazamine with conventional anticancer treatments is particularly effective. As of 2006, tirapazamine is undergoing phase III testing in patients with head and neck cancer and gynecological cancer, and similar trials are being undertaken for other solid tumor types.

Chemically it is an aromatic heterocycle di-N-oxide. Its full chemical name is 3-amino-1,2,4-benzotriazine-1,4 dioxide. Originally it was prepared in a programme screening for new herbicides in 1972. Its clinical use was first described by Zeman et al in 1986.

yuzai


  Alert | IP Printer-friendly page | Edit | Reply | Reply With Quote | Top

Conferences | Topics | Previous Topic | Next Topic